FDA Issues Public Health Advisory for Trasylol (Full Summary)
The Food and Drug Administration today issued a Public Health Advisory alerting doctors who perform heart bypass surgery, and their patients, that Trasyolol (aprotinin injection), a drug used to prevent blood loss during surgery, has been linked in two scientific publications to higher risks of serious side effects including kidney problems, heart attacks and strokes in patients who undergo artery bypass graft surgery.
HealthGrades finds top hospitals have 27% lower mortality risk
...a "clear and profound divergence between the best hospitals and all others,"...
Bolus Injection of Adenosine Before Cardioplegic Induction Improves Postischemic Global Function in Coronary Artery Bypass Grafting
The purpose of the present study was, therefore, to assess the clinical relevance of intra-aortic administration of adenosine following aortic cross-clamping with respect to the exertion of additional protection in routine coronary artery bypass surgery.
Does the Rate of Rewarming from Profound Hypothermic Arrest Influence the Outcome in a Swine Model of Lethal Hemorrhage?
This experiment was designed to test the impact of different warming rates on outcome in a swine model of lethal hemorrhage from complex vascular injuries.
Effects of Intra-Aortic Balloon Counterpulsation on Parameters of Tissue Oxygenation
To investigate the effects of intra-aortic balloon pump therapy on parameters of global and regional oxygenation in patients undergoing cardiac surgery.
A Perfusion Conference at Sea October 13-21, 2007
A cruise conference is a unique alternative to traditional land-based resort programs as less expensive. Group cruising offers visual activity while interfacing conference participants in a relaxed and pleasurable setting. A cruise meeting will motivate-inspire-educate-revitalize attendees at sea with all the luxury and elegance that only an ocean liner offers in a self contained environment. We assure that the objectives-expectations-budget allocations will be achieved as an excellent return on your investment.
PHVT Disruptive Technology Could Revolutionize Heart Failure Treatment
The early clinical promise of percutaneous heart valve technology-a group of minimally invasive devices designed to treat cardiac valve dysfunction without the need for cardiopulmonary bypass-could one day play a prominent role in curbing the costs associated with treating heart failure, which is the current number-one driver of hospitalization among Medicare patients.
The Risk Associated with Aprotinin in Cardiac Surgery
In this observational study involving 4374 patients undergoing revascularization, we prospectively assessed three agents (aprotinin [1295 patients], aminocaproic acid [883], and tranexamic acid [822]) as compared with no agent (1374 patients) with regard to serious outcomes by propensity and multivariable methods.
The Risk Associated with Aprotinin in Cardiac Surgery
In this observational study involving 4374 patients undergoing revascularization, we prospectively assessed three agents (aprotinin [1295 patients], aminocaproic acid [883], and tranexamic acid [822]) as compared with no agent (1374 patients) with regard to serious outcomes by propensity and multivariable methods.
Bayer HealthCare Response: The Risk Associated with Aprotinin in Cardiac Surgery
Bayer has only just become aware of this observational study and we have not yet had an opportunity to receive and review the data from which the authors derived their conclusions.
The Risk Associated with Aprotinin in Cardiac Surgery
In this observational study involving 4374 patients undergoing revascularization, we prospectively assessed three agents (aprotinin [1295 patients], aminocaproic acid [883], and tranexamic acid [822]) as compared with no agent (1374 patients) with regard to serious outcomes by propensity and multivariable methods.
Influence of Venous Drainage and Hemofiltration on Hypercirculatory Instability After High Volume Crystalloid Cardioplegia During Coronary Artery Bypass Surgery
This prospective study was undertaken in order to investigate the impact of the systemic infusion of high volume crystalloid cardioplegia on the incidence of hypercirculatory instability and inflammatory mediator release in patients undergoing coronary artery bypass grafting.